Dexelvucitabine
Dexelvucitabine (RVT) is a nucleoside reverse transcriptase inhibitor investigated for HIV treatment. It has been studied in vitro for its antiviral activity and in vivo within preclinical models of HIV infection, supporting its role as a research tool for antiretroviral development.
Product Specifications
CAS Number
134379-77-4
Product Name Alternative
DPC 817, DPC817, DPC-817, Dexelvucitabine, DFC, cytidine, beta-D-D-4FC, antiretroviral, b-D-D-4FC, 2′-deoxycytidine, Human immunodeficiency virus, HIV, HIV-1, D-D-4FC, d-d4FC, inhibit, Inhibitor, Nucleoside reverse transcriptase, nucleoside reverse transcriptase, M184V mutation, thymidine, RVT, resistant viruse, ReverseTranscriptase, Reverse Transcriptase, Reverset, viral polymerase, β-D-D-4FC
Field of Research
Infectious Disease & Virology, Protein Biochemistry
Purity
98.25% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (8.8 mM) ; DMSO:30 mg/mL (132.05 mM)
Smiles
[H][C@]1 (O[C@H] (CO) C=C1) n1cc (F) c (N) nc1=O
Molecular Formula
C9H10FN3O3
Molecular Weight
227.19
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6240759-01 0.1 mL
SPRED2 (Sprouty-Related, EVH1 Domain Containing 2, FLJ21897, FLJ31917, MGC163164, Spred-2) (MaxLight 750)
Sign In for Pricing
View Details MBS6240759-02 5x 0.1 mL
SPRED2 (Sprouty-Related, EVH1 Domain Containing 2, FLJ21897, FLJ31917, MGC163164, Spred-2) (MaxLight 750)
Sign In for Pricing
View Details